Author:
Stone William,Mahamar Almahamoudou,Sanogo Koualy,Sinaba Youssouf,Niambele Sidi M,Sacko Adama,Keita Sekouba,Youssouf Ahamadou,Diallo Makonon,Soumare Harouna M,Kaur Harparkash,Lanke Kjerstin,ter Heine Rob,Bradley John,Issiaka Djibrilla,Diawara Halimatou,Traore Sekou F,Bousema Teun,Drakeley Chris,Dicko Alassane
Funder
Bill & Melinda Gates Foundation
Subject
Virology,Infectious Diseases,Microbiology (medical),Microbiology
Reference30 articles.
1. Large-scale artemisinin–piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa;Deng;Clin Infect Dis,2018
2. Malaria medicines to address drug resistance and support malaria elimination efforts;Achan;Expert Rev Clin Pharmacol,2018
3. The use of artesunate–pyronaridine for the treatment of uncomplicated malaria,2019
4. Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study;Amaratunga;Lancet Infect Dis,2016
5. Artemether–lumefantrine versus dihydroartemisinin–piperaquine for treatment of malaria: a randomized trial;Kamya;PLoS Clin Trials,2007